The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
In keeping with a previously announced decision to divest its prescription (Rx) drug business and focus on consumer healthcare, Perrigo has appointed Murray S. Kessler, formerly Chief Executive Officer (CEO) of the Lorillard Tobacco Company, as...
The US Food and Drug Administration (FDA) has issued a draft guidance to help companies developing drug products for rare diseases conduct more efficient pre-investigational new drug application (pre-IND) meetings. The draft guidance specifically...
A federal appeals court has ruled four patents by Teva Pharmaceutical Industries’ invalid for its top-selling drug Copaxone (glatiramer acetate), a multiple sclerosis drug and Teva’s top-selling product. The US Court of Appeals for the Federal...
In a deal that would mark a new business model for healthcare delivery, the US Department of Justice (DOJ) has granted conditional approval for the $69-billion merger of CVS Health Corporation (CVS), the largest retail pharmacy chain in the...
Dr. Reddy’s Laboratories has agreed to sell its active pharmaceutical ingredient (API) manufacturing business unit in Hyderabad, India to Therapiva, a Hyderabad, India-based emerging generics pharmaceutical company and Neopharma joint venture...
AbbVie and Sandoz, Novartis’ generics arm, have signed a resolution of all intellectual property (IP)-related litigation concerning Sandoz’s Hyrimoz (adalimumab), a proposed biosimilar to AbbVie’s anti-inflammatory drug, Humira (adalimumab),...
GlaxoSmithKline (GSK) is closing part of its cephalosporins antibiotics manufacturing plant in Ulverston, England and planning staff reductions of approximately 200 employees. This follows a strategic review from which GSK decided to keep its...
Bayer is planning staff reductions of approximately 227 employees at its biologics manufacturing plant in Berkeley, California, which recently began production of its newly approved hemophilia A therapy, Jivi (antihemophilic factor [recombinant])....
Janssen Pharmaceuticals, one of the pharmaceutical companies of Johnson & Johnson, has formed a license and collaboration deal with Arrowhead Pharmaceuticals, a Pasadena, California-based biotechnology company, to develop and commercialize...
GlaxoSmithKline (GSK) has signed a three-year clinical manufacturing agreement with Hitachi Chemical Advanced Therapeutics Solutions (HCATS), an Allendale, New Jersey-based contract development and manufacturing organization.
Under the agreement,...
Novo Nordisk is planning staff reductions of approximately 250 employees in the US as part of a reorganization resulting from an assessment of resource needs against its business priorities. Last month (September 2018), the company announced staff...
Merck & Co. and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have partnered to discover, develop, and commercialize immunotherapies for patients with solid tumor cancers in a deal worth...
Sanofi has completed its previously announced divestment of its European generics business, Zentiva, to Advent International, a Boston-based private-equity firm, for approximately EUR 1.9 billion ($2.2 billion). The transaction was finalized ahead...
Roche has acquired Tusk Therapeutics, a Stevenage, UK-based pharmaceutical company focused on immuno-oncology, in a deal worth up to EUR 659 million ($759 million) ($80 million upfront and $675 million). Tusk has developed an antibody with a mode...
Merck & Co. and Accenture, a management consulting company, have partnered with Amazon Web Services (AWS) to launch a cloud-based informatics research platform designed to help organizations in the life-sciences industry improve productivity,...
